



# DR. H.A.S.H. Wellness Program

# **Cholelithiasis/es; Gallbladder stone management/removal**





**Medical history**

**Cholecystolithiases,  
fatty liver (MILD)**

## Labs done:

- (Maxicare October 23, 2022)
- Ultrasound (whole abdomen)

### ULTRASOUND REPORT

#### ULTRASOUND OF THE WHOLE ABDOMEN

The liver is not enlarged showing homogeneous parenchymal echopattern with slight increase in parenchymal echogenicity. The intrahepatic ducts are not dilated. No mass lesion noted.  
The gallbladder is physiologically distended measuring 2.1 cm in its transverse diameter with several hyperechoic foci exhibiting posterior acoustic shadowing with aggregate measurement of 3.7 cm. The GB wall is not thickened. The common duct measures 3.5 mm with no intraluminal echo.  
The pancreas is normal in size showing normal echotexture. No mass lesion or calcification noted.  
The spleen is normal in size and echopattern with smooth borders. No mass lesion noted.

Both kidneys are normal in size and parenchymal echogenicity with intact central echocomplexes. The renal cortical thicknesses are within normal limits. No calculus or focal mass noted.  
The right kidney measures 9.6 x 3.6 x 3.6 cm with corticomedullary thickness of 1.0 cm while the left kidney measures 10.7 x 5.4 x 5.4 cm with cortical thickness of 1.5 cm.  
The urinary bladder is distended with smooth mucosal lining. No intraluminal mass or calculus seen. Postvoid volume is minimal.  
The uterus is normal in size and anteverted. No focal mass seen. Both adnexae are unremarkable.

#### IMPRESSION:

**CHOLECYSTOLITHIASES.**

**MILD FATTY INFILTRATION OF THE LIVER.**

**ULTRASONICALLY NORMAL PANCREAS, SPLEEN, KIDNEYS, UTERUS, ADNEXAE AND URINARY BLADDER.**

- **Cholecystolithiases (3.7cms)**

- **Fatty Liver (MILD)**



- **Hospital Management > Cholecystectomy**

**CDC**

**+**



**PROGRAM**

## ULTRASOUND REPORT

### UPPER ABDOMEN ULTRASOUND

Liver is normal in size with increased echopattern. No focal mass lesion is seen. Gallbladder is normal in size with no intraluminal echoes seen. Its wall is not thickened. Intrahepatic and extrahepatic ducts are not dilated. Common bile duct measures 0.36 cm. Pancreas and spleen are normal in size and echopattern. No focal mass lesion is seen.

#### IMPRESSION:

HEPATIC STEATOSIS  
NORMAL SONOGRAM OF THE GALLBLADDER, PANCREAS AND SPLEEN  
NON DILATED DUCTS

## Labs done:

- (ExactCheck Diagnosis Center  
December 18, 2022)
- **Ultrasound (whole abdomen)**


”

- **Negative for Cholecystolithiases**
- **Fatty Liver (MILD)**



**Medical history**

**Cholelithiases**



## Labs done:

- (Global Medical Center of Laguna Inc March 04, 2023)
- **Ultrasound (whole abdomen)**

## Findings

**Cholelithiasis  
(2.64cms)**

- **Hospital Management > Cholecystectomy**

CDC

+



PROGRAM

## Labs done:

- (Hi-Precision Diagnostics  
May 03, 2023)
- Ultrasound (whole abdomen)



- **Negative for  
Cholelithiasis**

No previous study seen.  
Multiple transverse and longitudinal scans of the upper and lower abdomen were obtained.

#### LIVER:

It is normal in size with normal parenchymal echogenicity.  
No focal masses seen. Intrahepatic ducts are not dilated.  
Proximal common bile duct measures 0.3 cm.

#### IMPRESSION:

NO HEPATIC PATHOLOGY DETECTED SONOGRAPHICALLY.  
NON DILATED DUCTS.

GALLBLADDER: It measures 4.3 x 0.8 cm with no internal echoes seen. Its wall is not thickened.

IMPRESSION: PARTIALLY CONTRACTED GALLBLADDER.

#### PANCREAS AND SPLEEN:

Pancreas and spleen are not enlarged with homogenous parenchyma.

IMPRESSION: NO PANCREATIC AND SPLENIC PATHOLOGY DETECTED SONOGRAPHICALLY.

ABDOMINAL AORTA: The abdominal aorta measures 1.0 cm in its greatest AP diameter. No abnormal areas of dilatation seen. Paraaortic lymph nodes are not enlarged.

IMPRESSION: UNREMARKABLE ULTRASOUND OF THE ABDOMINAL AORTA.

#### KIDNEYS:

Both kidneys are normal in size and echo pattern.

Right kidney measures 9.6 x 4.2 cm with cortical thickness of 0.8 cm.


Left kidney measures 9.4 x 4.5 cm with cortical thickness of 0.7 cm.

No evidence of lithiasis or hydronephrosis bilaterally.

IMPRESSION: NO RENAL PATHOLOGY DETECTED SONOGRAPHICALLY.

Note: This report is based entirely on sonographic examination and should be correlated with clinical and laboratory findings.

# **Prostatomegaly/ Prostate enlargement**





## **Medical history**

**Fatty Liver,  
Cholelithiases,  
Prostatomegaly (Stage 2)**


## Labs done:

- (St. Claire Clinic - September 08, 2022)
- Ultrasound (Whole Abdomen)



- Fatty Liver
- Cholecystolithiasis (1.2cm)
- Prostatomegaly (Stage 2)

**Hospital management > Medications;  
TURP**



CDC

+




PROGRAM


## Labs done:

- (Sta. Elena Diagnostic Center - January 05, 2023)
- **Ultrasound (Whole Abdomen)**



- **Essentially normal liver**
- **Cholecystolithiasis down to (1.1cm)**
- **Essentially normal Prostate gland**





# **Chronic Kidney disease/Chronic Renal Failure**

## **Elevated BUN, Creatinine**




## Medical history

**Chronic Renal Failure;  
Hypertension x15 years;  
s/p Radical Nephrectomy,  
RIGHT**

### Medications:

- **Clonidine HCL 150mg/tab TID**
- **Amlodipine 10mg/tab OD**
- **Hemarate FA BID**
- **Sodium Bicarbonate (NaHCO<sub>3</sub>) 650mg/tab TID**
- **Rosuvastatin 10mg/tab OD HS**
- **Omacor OD**
- **Ketobest 600mg/tab 2 tabs TID**
- **Urinorm 40mg/tab OD**
- **Cranberry caps OD**
- **Sevelamer 800mg/tab**
- **Epoetin 4000 IU/ml once per week**



CHEMISTRY				
TEST/S	RESULT/S		REFERENCE VALUES	(SI UNITS)
Blood Urea Nitrogen	32.2	H	2.1 - 7.1	mmol/L
Creatinine	772.7	H	44.2 - 97.2	umol/L
FBS	4.57		3.89 - 5.50	mmol/L
HDL Cholesterol	0.76	L	1.04 - 1.50	mmol/L
LDL Cholesterol	0.73	L	2.59 - 4.11	mmol/L
Potassium	4.6		3.5 - 5.1	mmol/L
Sodium	139		136 - 145	mmol/L
Total Cholesterol	2.72		< 5.18	mmol/L
Alkaline Phosphatase	73.0		40.0 - 150.0	U/L
Direct Bilirubin	2.5		0 - 8.6	umol/L
Indirect Bilirubin	3.0	L	3.4 - 11.9	umol/L
Phosphorus	1.94	H	0.74 - 1.52	mmol/L
Total Bilirubin	5.5		3.4 - 20.5	umol/L
SGOT/AST	27		5 - 34	U/L
SGPT/ALT	31		0 - 55	U/L
Triglycerides	2.41	H	< 1.70	mmol/L
Uric Acid	0.38	H	0.15 - 0.37	mmol/L
VLDL	1.10			
Magnesium	1.11	H	0.66 - 1.07	mmol/L
Total Protein	78		64 - 83	g/L
Albumin	44		35 - 50	g/L
Globulin	34		23 - 35	g/L


## Labs done:

- (De La Salle University Medical Center March 29, 2023)
- Blood Chem



↑ **BUN**  
↑ **Creatinine**

- Hospital management
  - Hemodialysis
  - Kidney transplant



CDC

+

DR. H.A.S.H. **PROGRAM**  
ADVANCED REGENERATIVE MEDICINE

**CLINICAL CHEMISTRY**  
**BLOOD CHEMISTRY**

TEST NAME	S.I. UNIT		CONVENTIONAL UNIT	
	Result	Reference Range	Result	Reference Range
Creatinine	H 570	45 - 84 umol/L	6.44	0.51 - 0.95 mg/dL
Estimated Glomerular Filtration Rate (eGFR)	7	ml/min/1.73m <sup>2</sup>		
Urea Nitrogen (BUN)	H 23.5	2.1 - 7.1 mmol/L	65.82	5.88 - 19.89 mg/dL
BUN/Creatinine Ratio	10.21		10.21	

**REMARKS:**

CREATININE AND UREA NITROGEN: RESULT/S VERIFIED. TEST/S DONE TWICE.


Laboratory report must be clinically correlated by your attending physician.

**Labs done:**


- (New World Diagnostics  
May 12, 2023)
- Blood Chem



↓ BUN by (8.5)  
↓ Creatinine by  
(202.7)



# Patient/Male




**Medical History**

**Chronic Renal Disease (Stage 3 B);  
Prostatomegaly**

## Labs Done (Dec 2022):

- **Blood**
  - **UREA 8.49mmol/L**
  - **Creatinine 179.7mmol/L**
- **Ultrasound**
  - **RIGHT Kidney w/ Ureteropelvocaliectasia and Intraparenchymal Calcification 0.8cm**
  - **LEFT Kidney w/ mild pelvocaliectasia**
  - **Prostatomegaly**




CLINICAL CHEMISTRY

Age:	72 Year	Sample ID:	APC03
Gender:	Female	Sample Type:	Serum
		Department:	CPO
		Releasing Date:	12/14/2022

Chemistry	Result	Unit	Flag	Ref Range
UREA	8.49	mmol/L	H	2.80-7.20
CREA	179.7	µmol/L	H	44.0-80.0

- **Hospital management**
  - **Hemodialysis**
  - **Kidney transplant**



CDC

+



PROGRAM

## Labs Done (Feb 2023):

- **Blood**
  - **UREA 7.5mmol/L**
  - **Creatinine 159.1mmol/L**
- **Ultrasound**
  - **RIGHT Kidney Calcification reduced to 0.4cm**
  - **LEFT Kidney E/N**
  - **Prostate E/N**

Requested by:

Blood Chemistry	CONVENTIONAL	SI UNITS
BUN	31.21	8 - 20 mg/dL
Uric Acid	11.88	3 - 7 mg/dL
Creatinine	11.1	0.8 - 1.5 mg/dL
Cholesterol	169	150 - 200 mg/dL
Triglycerides	75	30 - 190 mg/dL
HDL-Cholesterol	60	> 35 mg/dL
LDL-Chol	94	60 - 120 mg/dL
VLDL-Chol	15	0 - 40 mg/dL
Chole / HDL Ratio	2.82	< 4
SGOT	23	8 - 40 U/L
SGPT	21	5 - 35 U/L
GGTP	34	8 - 35 U/L
HBA1C	5.4	4.5 - 6.2 %

The liver is normal in size and parenchymal echogenicity. The right liver lobe measures 11.5 cm while the left liver lobe measures 6.4 cm. No focal mass lesion seen.

The gallbladder is normal in size and configuration with non-thickened wall. It measures 4.3 x 2.2 x 2.3 cm. No intraluminal intense echo noted.

The intrahepatic and extrahepatic ducts are not dilated.

The pancreas is not visualized due to intervening bowel gas.

The spleen is normal in size and parenchymal echogenicity. No focal mass lesion seen.

Both kidneys are normal in size and parenchymal echogenicity. The right kidney measures 9.3 x 3.8 x 4.2 cm with parenchymal thickness of 1.35 cm while the left kidney measures 9.4 x 4.8 x 4.3 cm with parenchymal thickness of 1.26 cm. An intense echo with no acoustic shadowing is seen in the parenchyma of the superior pole of the right measuring 0.48 cm. No ectasia, nor focal mass lesion seen.


The prostate gland is normal in size with calcifications within. It measures 3.6 x 3.4 x 3.8 cm (weight = 25.6 g).

The urinary bladder is well distended with smooth and non-thickened wall. Prevoid urine volume is 111 cc with residual urine of 11 cc postvoid.

**IMPRESSION:** RENAL PARENCHYMAL CALCIFICATION, RIGHT PROSTATIC CONCRETIONS  
NEGATIVE ULTRASOUND STUDY OF THE LIVER, BILIARY TRACT, SPLEEN AND LEFT KIDNEY

The background is a soft watercolor illustration. It features large, overlapping washes of light pink and pale purple. Scattered throughout these washes are numerous small, detailed flowers in shades of pink, purple, and yellow, along with small green leaves. The overall effect is delicate and artistic.

# Breast Neoplasm



**38/Female**

**Medical history**

**G0P0;  $\geq$  2 Year HX of  
Breast Lesion, RIGHT**

**EXAMINATION:** 2D + 3D BREAST ULTRASOUND

**HISTORY:** (+) FAMILY HISTORY OF BREAST CA - SISTER AND GRANDMOTHER

**COMPARISON:** FOLLOW - UP STUDY TO JULY 2016

**INTERPRETATION AND FINDINGS**

Breast ultrasound revealed the following:

**[<LEFT BREAST>]**

No discrete mass lesion.

**[<RIGHT BREAST>]**

1. Complex nodule with intraductal component at 3A position measuring 0.6 x 0.4 x 0.6 cm. TISSUE CORRELATION is recommended.

**IMPRESSION:**

TISSUE CORRELATION is recommended for the complex nodule in the right breast  
Unremarkable left breast

**AXILLARY AREAS:** Axillary regions show no abnormality

**BIRADS CATEGORY: 4**

**BIRADS CATEGORY**

Category 0 - Incomplete - Additional imaging evaluation needed before final assessment  
Category 1 - Negative - No lesion found (routine follow -up)  
Category 2 - Benign Finding - No malignant features: eg cyst (routine follow-up for age, clinical management)  
Category 3 - Probably benign finding: Malignancy is highly unlikely eg fibroadenoma (initial short interval follow-up)  
Category 4 - Suspicious abnormality - Low to moderate probability of cancer, biopsy should be considered  
Category 5 - Highly suggestive for malignancy: almost certainly cancer, appropriate action should be taken.  
Category 6 - Known cancer - Biopsy proven malignancy, prior to institution of therapy.

**Note:**

1. Not all breast abnormalities like microcalcifications or diffuse breast parenchymal changes show up on breast ultrasound, hence a stand-alone ultrasound examination cannot be used as a screening modality for early breast lesions.
2. Ultrasound, being complementary to mammography should be accompanied by a mammogram so that an accurate BIRADS category can be given.
3. Utilization of either or both modalities is based upon a patient's risk for breast cancer, clinical evaluation and expert opinion of the attending physician.

*This radiologic interpretation is only a part of the overall assessment of a patient's condition. It must be correlated with the clinical, laboratory and other ancillary parameters for a comprehensive analysis.*

**Hospital  
Management:**

**Excision  
Biopsy with  
or without  
Lumpectomy**



**Ultrasound Breast, Bilateral (May 2022)**

CDC

+



PROGRAM



# Ultrasound Breast, Bilateral (May 2023)




**PATIENTS THAT HAVE TAKEN  
THE PROGRAM**

# ADMITTED MALE PATIENT WITH DECUBITUS ULCER STAGE III



**PRE**



**POST**

# Male Patient w/ > 10 year history of severe eczema



**PR**



**POST**

# Male Patient w/ > 5 year history of severe eczema



PRE




POST

# Mission Statement

- **Mission**
- **Present premium health management options**
- **Deliver superior patient results by championing all aspects of natural and integrative medicine**
- **Vision**
- **Disrupt the healthcare landscape by utilizing evidence-based, holistic and integrative therapeutic methods**
- **Establish a world class healthcare facility offering the best healthcare solutions**

# Market Summary/Opportunities



# Business Concept

**As healthcare becomes more virtual, fragmented and specialized but limited; we empower patients by providing options to address the presenting health condition. We optimize health and wellbeing through evidence-based, sustainable, integrative approaches. WE provide HIGHLY EFFECTIVE, FULLY-CUSTOMIZABLE HEALTHCARE EXPERIENCES built on emphasizing the therapeutic relationship between practitioner and patient, as informed by evidence, which makes use of all appropriate therapies. We deliver BOLD, EFFECTIVE TREATMENTS with healing-oriented medicine that takes account of the whole person, including all aspects of lifestyle. By working together, WE EMPOWER THEM TO ACTIVELY SHAPE THEIR HEALTH JOURNEY.**